NASDAQ:MCRB Seres Therapeutics (MCRB) Stock Forecast, Price & News $5.60 +0.24 (+4.48%) (As of 06/8/2023 ET) Add Compare Share Share Today's Range$5.12▼$5.6050-Day Range$4.67▼$6.5552-Week Range$2.50▼$9.49Volume2.78 million shsAverage Volume2.11 million shsMarket Capitalization$716.24 millionP/E RatioN/ADividend YieldN/APrice Target$14.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Seres Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.83 Rating ScoreUpside/Downside150.0% Upside$14.00 Price TargetShort InterestBearish11.74% of Shares Sold ShortDividend StrengthN/ASustainability-1.14Upright™ Environmental ScoreNews Sentiment0.16Based on 3 Articles This WeekInsider TradingSelling Shares$36,527 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($0.89) to ($1.48) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.95 out of 5 starsMedical Sector553rd out of 986 stocksPharmaceutical Preparations Industry257th out of 471 stocks 3.4 Analyst's Opinion Consensus RatingSeres Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $14.00, Seres Therapeutics has a forecasted upside of 150.0% from its current price of $5.60.Amount of Analyst CoverageSeres Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted11.74% of the outstanding shares of Seres Therapeutics have been sold short.Short Interest Ratio / Days to CoverSeres Therapeutics has a short interest ratio ("days to cover") of 5.4.Change versus previous monthShort interest in Seres Therapeutics has recently increased by 23.23%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldSeres Therapeutics does not currently pay a dividend.Dividend GrowthSeres Therapeutics does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSeres Therapeutics has received a 71.59% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for infectious diseases", "Clinical research services for physiological diseases ", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Seres Therapeutics is -1.14. Previous Next 1.2 News and Social Media Coverage News SentimentSeres Therapeutics has a news sentiment score of 0.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.50 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Seres Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 46 people have searched for MCRB on MarketBeat in the last 30 days. This is a decrease of -56% compared to the previous 30 days.MarketBeat FollowsOnly 9 people have added Seres Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -59% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Seres Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $36,527.00 in company stock.Percentage Held by InsidersOnly 4.80% of the stock of Seres Therapeutics is held by insiders.Percentage Held by Institutions90.16% of the stock of Seres Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Seres Therapeutics are expected to decrease in the coming year, from ($0.89) to ($1.48) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Seres Therapeutics is -2.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Seres Therapeutics is -2.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSeres Therapeutics has a P/B Ratio of 62.22. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Seres Therapeutics (NASDAQ:MCRB) StockSeres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.Read More Receive MCRB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Seres Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address MCRB Stock News HeadlinesJune 5, 2023 | msn.comSeres, Nestle Health announce US launch of c. diff therapy VowstJune 5, 2023 | finance.yahoo.comSeres Therapeutics and Nestlé Health Science Announce U.S. Commercial Availability of VOWST™, the First and Only FDA-Approved Microbiota-Based Oral Therapeutic for Prevention of Recurrence of C. Difficile InfectionJune 8, 2023 | Vantage Point (Ad)Stop Trading Like A TurtlePerforming at your best requires quick reaction and adaptability. While slow and steady progress works for some, having a tool that enables informed trading decisions is essential amid volatility. It's 2023. Why trade like a turtle when you could track down new opportunities like a cheetah? June 2, 2023 | finance.yahoo.comSeres Therapeutics to Present at Jefferies Healthcare ConferenceMay 30, 2023 | finance.yahoo.comSeres Therapeutics Announces Receipt of $125 Million Milestone From Nestlé Health Science Following FDA Approval of VOWST™May 27, 2023 | americanbankingnews.comSeres Therapeutics, Inc. (NASDAQ:MCRB) Receives $14.00 Consensus PT from BrokeragesMay 26, 2023 | americanbankingnews.comSeres Therapeutics (NASDAQ:MCRB) Shares Down 5.9% May 24, 2023 | americanbankingnews.comStockNews.com Downgrades Seres Therapeutics (NASDAQ:MCRB) to SellJune 8, 2023 | Vantage Point (Ad)Stop Trading Like A TurtlePerforming at your best requires quick reaction and adaptability. While slow and steady progress works for some, having a tool that enables informed trading decisions is essential amid volatility. It's 2023. Why trade like a turtle when you could track down new opportunities like a cheetah? May 23, 2023 | fool.comSeres Therapeutics (NASDAQ: MCRB)May 23, 2023 | seekingalpha.comSeres Q1 Earnings: Major News For InvestorsMay 22, 2023 | seekingalpha.comSeres Therapeutics: Still Work To Do Before Realizing Its PotentialMay 16, 2023 | finance.yahoo.comFlagship Pioneering Launches Metaphore Biotechnologies to Unlock the Therapeutic Potential of BiomimicryMay 16, 2023 | americanbankingnews.comChardan Capital Brokers Lift Earnings Estimates for Seres Therapeutics, Inc. (NASDAQ:MCRB)May 14, 2023 | americanbankingnews.comSeres Therapeutics (NASDAQ:MCRB) Raised to "Hold" at StockNews.comMay 8, 2023 | msn.comSeres Therapeutics Q1 2023 Earnings PreviewMay 8, 2023 | msn.comPreview: Seres Therapeutics's EarningsMay 8, 2023 | msn.comWeekly biotech pulse: Big catalysts on tap for Sarepta, Roche, Eyenovia, and moreMay 8, 2023 | finance.yahoo.comSeres Therapeutics and Nestlé Health Science Present Results from ECOSPOR IV Phase 3 Study of VOWST™, a Microbiota-Based Oral Therapeutic for Prevention of Recurrence of C. Difficile Infection, at the Digestive Disease Week (DDW) Annual MeetingMay 5, 2023 | msn.comUnusual Call Option Trade in Seres Therapeutics (MCRB) Worth $137.15KMay 5, 2023 | finance.yahoo.comSeres Therapeutics to Host First Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on May 9, 2023May 5, 2023 | americanbankingnews.comSeres Therapeutics (NASDAQ:MCRB) Sees Large Volume IncreaseMay 4, 2023 | americanbankingnews.comInsider Selling: Seres Therapeutics, Inc. (NASDAQ:MCRB) Insider Sells $36,527.22 in StockMay 3, 2023 | seekingalpha.comSeres Gets FDA Approval And The Share Price Goes Down!May 1, 2023 | americanbankingnews.comReviewing Seres Therapeutics (NASDAQ:MCRB) and Acer Therapeutics (NASDAQ:ACER)May 1, 2023 | markets.businessinsider.comGoldman Sachs Sticks to Its Sell Rating for Seres Therapeutics (MCRB)April 30, 2023 | americanbankingnews.comBrokerages Set Seres Therapeutics, Inc. (NASDAQ:MCRB) Target Price at $14.40See More Headlines MCRB Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MCRB Company Calendar Last Earnings5/09/2023Today6/08/2023Next Earnings (Estimated)8/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MCRB CUSIPN/A CIK1609809 Webwww.serestherapeutics.com Phone(617) 945-9626FaxN/AEmployees333Year FoundedN/APrice Target and Rating Average Stock Price Forecast$14.00 High Stock Price Forecast$25.00 Low Stock Price Forecast$7.00 Forecasted Upside/Downside+150.0%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($2.30) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-250,160,000.00 Net Margins-3,509.50% Pretax Margin-5,177.14% Return on Equity-1,977.08% Return on Assets-87.94% Debt Debt-to-Equity Ratio4.69 Current Ratio1.82 Quick Ratio1.82 Sales & Book Value Annual Sales$7.13 million Price / Sales100.45 Cash FlowN/A Price / Cash FlowN/A Book Value$0.09 per share Price / Book62.22Miscellaneous Outstanding Shares127,900,000Free Float121,762,000Market Cap$716.24 million OptionableOptionable Beta2.65 Key ExecutivesEric D. ShaffPresident, Chief Executive Officer & DirectorMarcus ChapmanSenior Vice President-OperationsDavid A. ArkowitzCFO, Executive VP & Head-Business DevelopmentMatthew R. HennChief Scientific Officer & Executive VPBarbara McGovernVice President-Medical AffairsKey CompetitorsGH ResearchNASDAQ:GHRSBioXcel TherapeuticsNASDAQ:BTAI2seventy bioNASDAQ:TSVTMineralys TherapeuticsNASDAQ:MLYSOcular TherapeutixNASDAQ:OCULView All CompetitorsInsiders & InstitutionsProShare Advisors LLCSold 2,441 shares on 5/26/2023Ownership: 0.013%JPMorgan Chase & Co.Bought 11,472 shares on 5/18/2023Ownership: 0.488%New York State Common Retirement FundSold 16,500 shares on 5/18/2023Ownership: 0.025%Susquehanna International Group LLPBought 10,300 shares on 5/16/2023Ownership: 0.000%Jane Street Group LLCSold 44,000 shares on 5/16/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions MCRB Stock - Frequently Asked Questions Should I buy or sell Seres Therapeutics stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Seres Therapeutics in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MCRB shares. View MCRB analyst ratings or view top-rated stocks. What is Seres Therapeutics' stock price forecast for 2023? 5 brokerages have issued 12-month price targets for Seres Therapeutics' stock. Their MCRB share price forecasts range from $7.00 to $25.00. On average, they predict the company's share price to reach $14.00 in the next year. This suggests a possible upside of 150.0% from the stock's current price. View analysts price targets for MCRB or view top-rated stocks among Wall Street analysts. How have MCRB shares performed in 2023? Seres Therapeutics' stock was trading at $5.60 at the beginning of the year. Since then, MCRB stock has increased by 0.0% and is now trading at $5.60. View the best growth stocks for 2023 here. Are investors shorting Seres Therapeutics? Seres Therapeutics saw a increase in short interest in May. As of May 15th, there was short interest totaling 15,010,000 shares, an increase of 23.2% from the April 30th total of 12,180,000 shares. Based on an average trading volume of 2,770,000 shares, the short-interest ratio is currently 5.4 days. View Seres Therapeutics' Short Interest. When is Seres Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023. View our MCRB earnings forecast. How were Seres Therapeutics' earnings last quarter? Seres Therapeutics, Inc. (NASDAQ:MCRB) issued its earnings results on Tuesday, May, 9th. The biotechnology company reported ($0.57) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.57). The biotechnology company had revenue of ($0.52) million for the quarter, compared to analyst estimates of $1.58 million. Seres Therapeutics had a negative trailing twelve-month return on equity of 1,977.08% and a negative net margin of 3,509.50%. The business's revenue for the quarter was down 134.8% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.61) earnings per share. What ETFs hold Seres Therapeutics' stock? ETFs with the largest weight of Seres Therapeutics (NASDAQ:MCRB) stock in their portfolio include Simplify Propel Opportunities ETF (SURI), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Principal Healthcare Innovators ETF (BTEC), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Invesco Nasdaq Biotechnology ETF (IBBQ), iShares Biotechnology ETF (IBB) and ProShares Ultra Nasdaq Biotechnology (BIB). What other stocks do shareholders of Seres Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Seres Therapeutics investors own include OPKO Health (OPK), TherapeuticsMD (TXMD), Juno Therapeutics (JUNO), NVIDIA (NVDA), Walt Disney (DIS), Alibaba Group (BABA), Novavax (NVAX), Advanced Micro Devices (AMD), Dynavax Technologies (DVAX) and Gilead Sciences (GILD). When did Seres Therapeutics IPO? (MCRB) raised $101 million in an initial public offering (IPO) on Friday, June 26th 2015. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and BofA Merrill Lynch served as the underwriters for the IPO and Leerink Partners and Canaccord Genuity were co-managers. What is Seres Therapeutics' stock symbol? Seres Therapeutics trades on the NASDAQ under the ticker symbol "MCRB." Who are Seres Therapeutics' major shareholders? Seres Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include FMR LLC (14.79%), Federated Hermes Inc. (11.95%), BlackRock Inc. (4.89%), State Street Corp (2.95%), Geode Capital Management LLC (1.28%) and Avoro Capital Advisors LLC (1.01%). Insiders that own company stock include David S Ege and Health Ltp Fund Ge Nutritional. View institutional ownership trends. How do I buy shares of Seres Therapeutics? Shares of MCRB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Seres Therapeutics' stock price today? One share of MCRB stock can currently be purchased for approximately $5.60. How much money does Seres Therapeutics make? Seres Therapeutics (NASDAQ:MCRB) has a market capitalization of $716.24 million and generates $7.13 million in revenue each year. The biotechnology company earns $-250,160,000.00 in net income (profit) each year or ($2.30) on an earnings per share basis. How many employees does Seres Therapeutics have? The company employs 333 workers across the globe. How can I contact Seres Therapeutics? Seres Therapeutics' mailing address is 200 SIDNEY STREET - 4TH FLOOR, CAMBRIDGE MA, 02139. The official website for the company is www.serestherapeutics.com. The biotechnology company can be reached via phone at (617) 945-9626 or via email at ctanzi@serestherapeutics.com. This page (NASDAQ:MCRB) was last updated on 6/9/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Seres Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.